Aprotinin attenuates platelet accumulation in ischaemia-reperfusion- injured porcine skeletal muscle

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 4, 1999, Pages 157-165

  Birk Sørensen, Lene ^a,b   Fuglsang, J ^a   Sorensen H B ^a,b   Kerrigan, C L ^d   Petersen, L C ^c   Ravn, H B ^a   Hjortdal, V E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d Section Skejby ^*

Author keywords

Aprotinin; Ischaemia; Ischaemia reperfusion; Neutrophils; Platelet; PMN; Regional blood flow; Serine proteinase inhibitors; Skeletal muscle; Swine

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; RECOMBINANT APROTININ; SERINE PROTEINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD FLOW; CONTROLLED STUDY; FEMALE; ISCHEMIA; LATISSIMUS DORSI FLAP; MYOCUTANEOUS FLAP; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SKELETAL MUSCLE; SURVIVAL; SWINE; THROMBOCYTE AGGREGATION;

EID: 0032766972     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199906000-00001     Document Type: Review

References (62)

1. 1. Lee C, Kerrigan CL. Neutrophil localization following reperfusion of ischemic skin flaps. Plast Reconstr Surg 1992; 89: 910-915.
2. 2. Smith JK, Grisham MB, Granger DN, Korthuis RJ. Free radical defense mechanisms and neutrophil infiltration in postischemic skeletal muscle. Am J Physiol 1989; 256: H789-H793.
3. 3. Lee C, Kerrigan CL, Picard-Ami LAJ. Cyclophosphamide-induced neutropenia: effect on postischemic skin-flap survival. Plast Reconstr Surg 1992; 89: 1092-1097.
4. 4. Seekamp A, Mulligan MS, Till GO, Ward PA. Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury. Am J Pathol 1993; 142: 1217-1226.
5. 5. Korthuis RJ, Grisham MB, Granger DN. Leukocyte depletion attenuates vascular injury in postischemic skeletal muscle. Am J Physiol 1988; 254: H823-H827.
6. 6. Hjortdal VE, Sinclair T, Kerrigan CL, Solymoss S. Arterial ischemia in skin flaps: microcirculatory intravascular thrombosis. Plast Reconstr Surg 1994; 93: 375-385.
7. 7. Hjortdal VE, Sinclair T, Kerrigan CL, Solymoss S. Venous ischemia in skin flaps: microcirculatory intravascular thrombosis. Plast Reconstr Surg 1994; 93: 366-374.
8. 8. Hartsock LA, Seaber AV, Urbaniak JR. Intravascular thrombosis in skeletal muscle microcirculation after ischemia. Microsurgery 1989; 10: 161.
9. 9. Quinones Baldrich WJ. The role of fibrinolysis during reperfusion of ischemic skeletal muscle. Microcirc Endothelium Lymphatics 1989; 5: 299-314.
10. 10. Soeparwata R, Hartman AR, Frerichmann U, Stefano GB, Scheld HH, Bilfinger TV. Aprotinin diminishes inflammatory processes. Int J Cardiol 1996; 53 (suppl): S55-S63.
11. 11. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9.
12. 12. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-372.
13. 13. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-796.
14. 14. Wahba A, Black G, Koksch M, Rothe G, Preuner J, Schmitz G, et al. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb Haemost 1996; 75: 844-848.
15. 15. Laurel MT, Ratnoff OD, Everson B. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). J Lab Clin Med 1992; 119: 580-585.
16. 16. van den Besselaar AM, Dirven R, Bertina RM. Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol). Thromb Haemost 1993; 69: 298-299.
17. 17. Hallett MB, Shandall A, Young HL. Mechanism of protection against 'reperfusion injury' by aprotinin. Roles of polymorphonuclear leucocytes and oxygen radicals. Biochem Pharmacol 1985; 34: 1757-1761.
18. 18. Sunamori M, Innami R, Amano J, Suzuki A, Harrison CE. Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model. J Thorac Cardiovasc Surg 1988; 96: 314-320.
19. 19. Gurevitch J, Barak J, Hochhauser E, Paz Y, Yakirevich V. Aprotinin improves myocardial recovery after ischemia and reperfusion. Effects of the drug on isolated rat hearts. J Thorac Cardiovasc Surg 1994; 108: 109-118.
20. 20. Diaz PE, Fishbein MC, Davis MA, Askenazi J, Maroko PR. Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog. Am J Cardiol 1977; 40: 541-549.
21. 21. Samama CM, Mazoyer E, Bruneval P, Ciostek P, Bonnin P, Bonneau M, et al. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb Haemost 1994; 71: 663-669.
22. 22. van der Meer J, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van Ommen, et al. Aprotinin in aortocoronary bypass surgery: increased risk of veingraft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996; 75: 1-3.
23. 23. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1036.
24. 24. Bukhari EA, Krukenkamp IB, Burns PG, Gaudette GR, Schulman JJ, Al Fagih, et al. Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 1995; 60: 307-310.
25. 25. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 651-656.
26. 26. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-2244.
27. 27. Daniel RK, Kerrigan CL. The omnipotential pig buttock flap. Plast Reconstr Surg 1982; 70: 11-15.
28. 28. Royston D. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. Blood Coag Fibrinol 1990; 1: 55-69.
29. 29. Jochum M, Jonakova V, Dittmer H, Fritz H. An enzymatic assay convenient for control of aprotinin levels during proteinase inhibitor therapy. Fresenius Z Anal Chem 1984; 317: 719-720.
30. 30. Labbe R, Lindsay T, Gatley R, Romaschin A, Mickle D, Wilson G, et al. Quantitation of postischemic skeletal muscle necrosis: histochemical and radioisotopic techniques. J Surg Res 1988; 44: 45-53.
31. 31. Morris SF, Pang CY, Zhong A, Boyd B, Forrest CR. Assessment of ischemia-induced reperfusion injury in the pig latissimus dorsi myocutaneous flap model. Plast Reconstr Surg 1993; 92: 1162-1172.
32. 32. Hjortdal VE, Hansen ES, Kjolseth D, Henriksen TB, Gottrup F, et al. Arterio-venous shunting and regional blood flow in myocutaneous island flaps. An experimental study in pigs. Plast Reconstr Surg 1991; 87: 326-334.
33. 33. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
34. 34. Lee C, Kerrigan CL. Ibuprofen: treatment of ischemic musculocutaneous flaps. Ann Plast Surg 1994; 32: 300-304.
35. 35. Wang C, Stotland MA, Kerrigan CL. [abstract]. The effects of TNF in ischemia/reperfusion injury of myocutaneous flaps and skin flaps. Plastic Surgery Research Council, 40th Annual Meeting. New York University Medical Center; 1995. pp. 141-143.
36. 36. Stotland MA, Kerrigan CL. The role of platelet-activating factor in musculocutaneous flap reperfusion injury. Plast Reconstr Surg 1997; 99: 1989-1999.
37. 37. Stotland MA, Kerrigan CL. E-and L-selectin adhesion molecules in musculocutaneous flap reperfusion injury. Plast Reconstr Surg 1997, 99: 2010-2020.
38. 38. Birk-Sorensen L, Kerrigan CL, Wang C. Platelet activating factor antagonism in pure skin flaps exposed to ischaemia-reperfusion injury. Scand J Plast Reconstr Surg Hand Surg 1998, 32: 365-371.
39. 39. Birk-Sorensen L, Kerrigan CL, Jensen GS. E-selectin and L-selectin blockade in pure skin flaps exposed to ischaemia and reperfusion injury. Scand J Plast Reconstr Surg Hand Surg 1998, 32: 365-371.
40. 40. Birk-Sorensen L, Tromborg HB, Kerrigan CL, Solymoss S, Hjortdal VE. Sedimentation of formed elements in distally ischaemic flaps. Scand J Plast Reconstr Surg Hand Surg 1997; 31: 203-211.
41. 41. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033-1041.
42. 42. Baele PL, Ruiz Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg 1992; 43: 103-112.
43. 43. Goldstein DJ, DeRosa CM, Seldomridge JA, Weinberg AD, Oz MC, et al. Is aprotinin indicated for reoperative valvular surgery? J Heart Valve Dis 1997; 6: 88-92.
44. 44. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 479-494.
45. 45. Espana F, Estelles A, Griffin JH, Aznar J, Gilabert J. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. Thromb Res 1989; 56: 751-756.
46. 46. Chabbat J, Porte P, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993; 71: 205-215.
47. 47. Pintigny D, Dachary Prigent J. Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and an enzymatic study. Eur J Biochem 1992; 207: 89-95.
48. 48. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coag Fibrinol 1994; 5: 537-542.
49. 49. Christensen U, Schiodt J. Effects of aprotinin on coagulation and fibrinolysis enzymes. Fibrinol Proteol 1997; 11: 209-214.
50. 50. Montrucchio G, Lupia E, De Martino A, Silvestro L, Savu SR, Cacace G, et al. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. Circulation 1996; 93: 2152-2160.
51. 51. Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med 1995; 126: 377-384.
52. 52. Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997; 99: 1729-1738.
53. 53. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998; 95: 8298-8303.
54. 54. Terry CM, Callahan KS. Protein kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells. J Lab Clin Med 1996; 127: 81-93.
55. 55. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15: 612-621.
56. 56. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993; 143: 453-463.
57. 57. Koga S, Ogawa S, Kuwabara K, Brett J, Leavy JA, Ryan J, et al. Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. J Clin Invest 1992; 90: 1007-1015.
58. 58. Mortier E, Ongenac M, Van Aken J, Den Blauwen N, Rolly G. Evaluation of the anticoagulant properties of aprotinin in vitro. Eur J Anaesthesiol 1996; 13: 468-470.
59. 59. Haas S, Ketterl R, Stemberger A, Wendt P, Fritsche HM, Kienzle H, et al. The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement - a double blind clinical trial. Adv Exp Med Biol 1984; 167: 287-297.
60. 60. Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992; 86(suppl 11): II410-II412.
61. 61. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-834.
62. 62. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997; 96: 569-574.